Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 22, 2026
DEA admits the GAO report and denies reopening the hearing
$TRLVMedical cannabisOperating cashTax and regulatory risk
TRLV Stock Hub: Trulieve News, Medical Cannabis and Cash Flow
Trulieve’s medical platform generates cash, while Harvest accounting, legacy taxes and financial commitments shape how much remains for shareholders. The next results call is November 5. October 30 close: $10.28.
Full research report · PDF
Trulieve ($TRLV), research as of October 20, 2026
15 pages covering the Harvest separation, cash-flow quality, legacy tax exposure, debt, Georgia expansion and Connected licensing. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next announced reporting event
November 5, 2026 · 8:30 a.m. Eastern
Trulieve will discuss third-quarter results after releasing the figures. Cash conversion, the reporting perimeter and financial commitments matter alongside medical-market growth.
A separate October 22 DEA order permits optional reply briefs through November 5; the stay expires at the end of briefing. The order does not decide final rescheduling or authorize a Texas launch.
TRLV stock at a glance
Close · October 30, 2026
$10.28
Regular session; -3.02% versus $10.6000 on October 29.
H1 calculated free cash flow
$74.352M
Operating cash less capital expenditure; before other claims. Primary source
Where Trulieve stands now
Trulieve’s investment question begins with the cash produced by its medical business and ends with the claims against that cash. The NYSE listing and the Delaware move widen its capital-market framework, while the separation of mixed-use Harvest operations changes what the consolidated accounts contain. A large reported loss can therefore coexist with positive cash generation. That does not remove the need to assess deferred tax disputes, debt service and the quality of the remaining business. The October 22 DEA order admitted the GAO report and denied reopening the hearing, with optional reply briefs due November 5 and the stay extending through completion of that briefing schedule.
Operating cash does not remove legacy tax exposure. Positive cash generation coexists with disputed legacy tax claims, debt and leases. The Connected agreement leaves a Texas launch conditional on final licensing and regulatory approval.
The constructive case
Bull case. The medical platform retains patients and margins while Georgia’s expanded program and a licensed Texas launch add useful demand. Management services collect cash from Harvest, and clearer reporting allows investors to separate the recurring medical operation from the structural accounting charge. A favorable resolution of legacy tax issues would improve financial flexibility, but that outcome belongs to the scenario rather than the reported facts.
The cautious case
Bear case. Price competition erodes margins, new-market spending precedes adequate sales, or Harvest’s investment value and related-party collections deteriorate. An adverse tax resolution could require resources that headline free cash flow does not reserve. The loss on deconsolidation is primarily non-cash, but other risks can still become real cash obligations.
Latest Trulieve news
Oct 22, 2026
DEA admits the GAO report and denies reopening the hearing
The order admits the GAO report, denies reopening the hearing and permits optional supplemental briefs by October 29 and replies by November 5. The matter remains stayed until the briefing period closes, when the stay expires by its own terms. This is a procedural order, not a final rescheduling decision.
Oct 14, 2026
DEA order set a response deadline in the stayed proceeding
The Chief Administrative Law Judge granted leave to reply, reserved the question of admitting the GAO report and ordered the government to respond to the motion to reopen by October 21. Those were procedural directions, not a final rescheduling decision; the stated deadline has passed.
Oct 7, 2026
Florida mortgage repaid before maturity
Trulieve announced repayment of approximately $65 million of mortgage notes using operating cash. The company said debt falls to approximately $225 million; the release does not disclose the original rate or maturity.
Oct 6, 2026
Third-quarter results call scheduled for November 5
The announced call begins at 8:30 a.m. Eastern Time after release of the results. The scheduling announcement contains no quarterly financial results.
Sep 28, 2026
Connected and Alien Labs licensing agreement
The exclusive, perpetual, royalty-free license covers Florida and Texas. Texas launch still requires final permissions; royalty-free does not establish that every part of the arrangement has no cost.
Sep 22, 2026
Index inclusion announced
Trulieve announced inclusion in the S&P Total Market and S&P Completion indices. The announcement does not quantify fund inflows or operating value.
TRLV stock catalysts: earnings and licensed expansion
- November 5 — Q3 results conference call at 8:30 a.m. Eastern Time. Announced event
- Texas expansion — Connected and Alien Labs launch remains subject to final licensing and regulatory approval. Conditional
- November 5 — Optional DEA reply briefs due; stay runs through the briefing schedule under the October 22 order. Procedural deadline
Company earnings schedule · Connected agreement · DEA order of October 22
TRLV earnings, cash quality and legacy tax claims
Trulieve generated US$108.847 million of operating cash in the six months ended June 30, 2026, compared with US$137.224 million in the prior-year half. Quarterly report, cash-flow statement This is actual reported GAAP operating cash, rather than an adjusted earnings measure described with the word cash. It remains an important strength of the medical platform.
The August 7, 2026 release reports US$53.1 million of operating cash for the June quarter versus US$55.7 million for the March quarter, and company-defined free cash flow of US$32.1 million versus US$42.2 million. Quarterly results and free-cash-flow reconciliation The sequential figures make clear that positive generation does not imply an accelerating quarter.
The treatment of the current medical business and the dispute over earlier tax years are separate matters. Trulieve’s June filing reflects the company’s interpretation of the medical rescheduling rule for the current tax year. It also retains a large liability for earlier uncertain tax positions. A favorable current treatment does not extend backward without evidence of a settlement, ruling or accounting recognition.
Trulieve: Harvest accounting and financial obligations
The June 3 agreement identifies Whitley Holding 05192026, LLC as the Harvest investor. It acquired voting units carrying a 10% economic interest for approximately $14.8 million and appointed Frank Whitley and Rudy Rowe to the Harvest board; Trulieve’s subsidiary appointed Kim Rivers. Trulieve SEC filing, June 2026.
Cash and cash equivalents at June 30, 2026 were US$325.420 million, up from US$255.535 million at December 31, 2025. Quarterly report, balance sheet The increase does not equal operating cash retained after all activity. The first-half cash-flow statement also includes borrowing, capital expenditure and cash that left the consolidated group through Harvest.
Merlintrader Health Score · $TRLV
3.10out of 5
Assessed October 1, 2026. Weighted calculation: 3.0×30% + 3.0×30% + 3.0×20% + 3.5×10% + 3.5×10% = 3.10. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Legacy tax exposure is distinct from positive reported operating cash.
- Harvest’s deconsolidation changes the comparison with earlier consolidated revenue.
- Texas remains conditional; a licensing agreement is not permission to launch.
- Debt service, leases, capital expenditure and repurchases compete for cash.
TRLV Stock FAQ: Trulieve Questions Answered
Is the Harvest loss the same as cash spent?
No. The deconsolidation charge primarily measures the difference between the derecognized net assets and the fair value of the retained interest. The cash-flow statement separately identifies the cash that left the consolidated group. Both belong in the analysis. Source.
Has the legacy tax dispute been resolved?
The latest quarterly disclosure retains the liability for earlier uncertain tax positions and describes an ongoing IRS appeals process. A change in the current medical tax treatment is not evidence that the earlier claims have been settled. Source.
Does the Connected agreement mean Texas sales have started?
No. The agreement provides specified rights, while the company’s announcement retains the condition of final Texas licensing and regulatory approval. Contractual preparation and permission to operate are separate milestones. Source.
Does the buyback authorization mean shares were already repurchased?
No. The authorization sets discretionary limits and the latest quarterly note says there were no purchases under it by the reporting date. Later execution requires a subsequent company disclosure. Source.
What evidence would most change the current reading?
Results for the medical platform after the separation, collection of related-party receivables, a formal legacy-tax development and final Texas permissions would be more informative than treating exchange access or a contract alone as operating growth. Source.
Primary sources
- October 22, 2026 — DEA admits the GAO report and denies reopening the hearing
- October 14, 2026 — DEA order set a response deadline in the stayed proceeding
- October 7, 2026 — Florida mortgage repaid before maturity
- October 6, 2026 — Third-quarter results call scheduled for November 5
- September 28, 2026 — Connected and Alien Labs licensing agreement
- September 22, 2026 — Index inclusion announced
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $TRLV or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Cannabis companies carry regulatory, operating and financing risks. Changes in laws and licensing, restrictions on market access, pricing pressure and difficulties generating cash can affect their business. Companies may need to raise capital, and new equity can dilute existing shareholders. Regulatory progress does not guarantee commercial success or investment returns. Investors can lose some or all of their capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
